plantation model using wild-type bone marrow cells has been shown to cure symptoms 15 . A similar treatment strategy using gene-modified bone marrow cells has been shown to restore declines in general activity, rearing behavior and food intake in an experimental model of induced Parkinson's disease 16, 17 . Collectively, these studies demonstrate the therapeutic potential of normal or gene-modified microglia, but the clinical translation of these results requires a source of autologous cells that can readily engraft in the diseased or injured brain, preferably without the need for lethal irradiation or busulfan-mediated myeloablation.
We report here the sequential differentiation of human iPSC into myeloid progenitor-like intermediate cells and then into cells with the phenotypic, transcriptional and in vitro functional characteristics of brain-derived microglia (iPS-MG). To demonstrate the potential in vivo use of such cells, we used murine iPS-MG generated using an analogous method to treat syngeneic intracranial malignant glioma in animals. The ability to generate human iPS-MG in particular may facilitate the study of the role of microglia in health and disease.
RESULTS

Human iPSCs differentiate into microglia-like cells via a hematopoietic progenitor-like intermediate cell
The well-characterized human iPSC line NCRM-5 was obtained from the NIH Center for Regenerative Medicine, and iNC-01 transgene-free human iPSC were generated from peripheral blood CD34 + hematopoietic stem or progenitor cells. Given the myeloid lineage of microglia, a two-stage protocol in which human iPSC were first differentiated into hematopoietic progenitor-like cells (iPS-HPC) and then into human iPS-MG was devised ( Fig. 1a) . NCRM-5 human iPSC were differentiated on Microglia reside in the healthy CNS in a resting but surveillant state 1, 2 and promote homeostasis through reciprocal signaling interactions with neurons. In response to CNS injury, microglia can migrate to sites of damage, secrete inflammatory cytokines, phagocytose foreign matter and debris, and generate reactive oxygen species [3] [4] [5] . Beneficial properties of microglia include activation of innate and adaptive immune responses during infections and stimulation of neuronal plasticity, neurite outgrowth and synaptogenesis following ischemic strokes. Microglia can secrete factors capable of destroying glioma cells in vitro 6, 7 and in vivo 8 , and the intratumoral injection of lipopolysaccharide (LPS) stimulates microglia and macrophages to diminish tumor growth in mice 9 . Recently, microglia derived from human subjects without glioma have been shown to induce the expression of genes that control cell-cycle arrest and differentiation and to markedly mitigate the sphere-forming capacity of glioma patient-derived brain tumor-initiating cells in culture 10 . Microglia may also contribute to the progression of diseases such multiple sclerosis, Parkinson's disease, HIV dementia, amyotrophic lateral sclerosis, Huntington's disease, Pick's disease, brain tumors and prion disease 4, 11 . In disorders such as Alzheimer's disease, microglia can have either positive or negative effects depending on the disease stage, the local microenvironment and the presence of diseaseassociated gene variants 12, 13 .
The therapeutic use of microglia has been demonstrated in experimental animal models of human diseases. Myeloablative conditioning with lethal irradiation or busulfan, followed by bone marrow transplantation, results in brain engraftment and microglial differentiation of myeloid progenitor cells 14 . In a genetically engineered murine model of obsessive-compulsive disorder, application of this conditioning-trans-Microglia are resident inflammatory cells of the CNS and have important roles in development, homeostasis and a variety of neurologic and psychiatric diseases. Difficulties in procuring human microglia have limited their study and hampered the clinical translation of microglia-based treatments shown to be effective in animal disease models. Here we report the differentiation of human induced pluripotent stem cells (iPSC) into microglia-like cells by exposure to defined factors and co-culture with astrocytes. These iPSC-derived microglia have the phenotype, gene expression profile and functional properties of brain-isolated microglia. Murine iPSC-derived microglia generated using a similar protocol have equivalent efficacy to primary brain-isolated microglia in treatment of murine syngeneic intracranial malignant gliomas. The ability to generate human microglia facilitates the further study of this important CNS cell type and raises the possibility of their use in personalized medicine applications. Figure 1 Human iPSCs are differentiated into microglia-like cells. (a) Schematic representation of the process used to differentiate human iPSCs into microglia-like cells. (b-j) Phenotypic staining at various steps of the differentiation process. Human iPSCs, stage 1 hematopoietic progenitor-like cells and stage 2 human iPS-microglia immunostained with antibodies to Nanog and Tra-1-81 (b,e,h), CD34 and CD43 (c,f,i) and CD11b and Iba1 (d,g,j), respectively. DAPI was used to visualize nuclei. The figure is representative of three independent experiments done in replicates (n = 6). Scale bars, 50 µm.
Figure 2
Phenotypic and genotypic analysis indicate human microglia-like cells. (a) Cells from stage 2 (human iPSC-MG) were harvested using CD11b + beads; immunocytochemical staining for microglial markers was carried out and analyzed by flow-cytometry. iPS-MG express CD11b, HLA-DR, Iba1, CD45, TREM-2 and CX3CR1 but do not express the macrophage marker CD206, T cell-stimulatory molecule-like CD86 or the myeloid lineage marker CD200R. Histogram, filled-primary antibody; blank, isotype control. The figure is representative of three independent experiments (n = 3). (b) Heat map and (c) three-dimensional principal component (PC) analysis examining expression levels of microglia genes between iPS-MG derived from iNC-01 and NCRM-5 (iMG iNC01 and iMG NCRM-5, respectively), human fetal brain-isolated microglia (fMG), DC, Mac and human iPSCs (iNC-01 and NCRM-5). Expression levels for each class were averaged from three independent cell culture or differentiation experiment samples (n = 3). within circular intracellular structures ( Fig. 3) . Following stimulation with phorbol myristate acetate (PMA), iPS-MG produce reactive oxygen species as evidenced by the oxidation and resulting green fluorescence of the CellROX green reagent indicator dye over time (Fig. 3) . 
Murine iPSCs differentiate into microglia-like cells via a hematopoietic progenitor-like intermediate
To demonstrate the potential therapeutic value of iPS-MG, murine iPS-MG were differentiated from murine iPSC using a two-stage method analogous to that for human iPS-MG ( Fig. 4a) . Murine iPSCs generated by lentiviral reprogramming of murine embryonic fibroblasts isolated iNC-01 and NCRM-5, from which the human iPS-MG were derived, and commercially obtained primary human fetal brain-isolated microglia. We generated 53,617 gene-fragment expression values per biological triplicate sample and the 60% of data found to be noise-biased was discarded. After subjecting the data to one-factor ANOVA under Benjamini and Hochberg false discovery rate multiple-comparison correction conditions, we restricted our analysis to 18,302 gene fragments with a corrected P < 0.05. Using Tukey's post hoc analysis, we then quantified the number of these differentially expressed genes having both P < 0.05 and an absolute fold-change in expression ≥ 1.5 (14,475 genes) in pairwise comparisons of all the experimental groups. Based on correlation-based clustering analysis, the gene expression patterns of iPS-MG resembled those of human fetal microglia as well as those of DC and Mac, consistent with differentiation toward the myeloid lineage. The cells that most differed from iPS-MG in terms of gene expression were iPSCs. These gene expression relationships can be visualized using correlationbased clustering ( Fig. 2b) and covariance-based principal component analysis ( Fig. 2c) for Ingenuity microglia annotated genes. Recently, a unique microglial gene signature has been identified in both fetal and adult human microglia 21 . This human microglial signature consists of six genes: P2RY12, GPR34, MERTK, C1QA, PROS1 and GAS6. We extracted individual gene expression data for these six microglia genes from the human microarray dataset described above and found that all six of these genes were highly expressed in the iPS-MG but not in the iPSC, Mac or DC ( Supplementary Fig. 2 ). Quantitative reverse-transcription PCR (RT-qPCR) analyses confirmed the expression of these genes in the iPS-MG but not the iPSC, with the exception of P2RY12, which was expressed in both but to a greater degree in iPS-MG ( Table 1) . Expression of this distinct microglial gene signature supports the microglia-like identity of the iPS-MG and distinguished them from other myeloid cell types such as DC and Mac.
Human iPS-MG demonstrate functional properties of microglia
In addition to expressing the unique microglial gene signature shown above, microglia-like cells should also demonstrate the characteristic functional properties of microglia, such as phagocytosis of foreign particles, the production of reactive oxygen species (ROS) and secretion of inflammatory cytokines. Under baseline culture conditions, iPS-MG actively phagocytosed pHrodo E. coli BioParticles conjugates, as evidenced by the acidification and resulting visualization of these red fluorescent particles a iPS-MG ( Fig. 4i,j) . On average, for every 1 × 10 6 murine iPSC, the yield of microglia-like cells was 3 × 10 6 . The iPS-MG also expressed CD39 and CD45 but not Ly6C, Ly6G, B220, Thy1.2 and NK1.1, a phenotypic profile that closely resembled that of neonatal brain-isolated microglia (nMG) ( Fig. 5a) 18, 22 . The yields following the differentiation of adult fibroblast derived iPSC were equivalent to those of embryonic fibroblast-derived iPSC. The gene expression signatures of murine iPSC, iPS-MG, nMG, adult brain-isolated microglia, bone marrow-derived macrophages, peritoneal macrophages and DC were compared. Also included in the analyses were Nestin + neural stem cells NSC, given previous reports of differentiation of embryonic stem (ES) cells into microglia using a neuronal differentiation protocol 23 . We generated 35,556 gene-fragment expression values per biological triplicate sample and the 20% of data found to be noise-biased was discarded. After subjecting the data to one-factor ANOVA under Benjamini and Hochberg false discovery rate multiple-comparison correction conditions, we restricted our analysis to 26,842 gene fragments with a corrected P <0.05. Using Tukey's post hoc analysis, we then quantified the number of these genes having both P < 0.05 and an absolute fold-change in expression ≥ 1.5 in pairwise comparisons of all the experimental groups, resulting in 20,232 genes. The results of this a posteriori analysis indicated that the gene expression patterns of iPS-MG most closely resembled those of nMG. The next-closest resemblance was to those of adult brain-isolated microglia. The cells that most differed from iPS-MG in terms of gene expression patterns were iPSCs and neural stem cells. These gene expression relationships can be visualized using correlation-based clustering ( Fig. 5b) and covariance-based principal component analyses ( Fig. 5c) .
Murine iPS-MG demonstrate in vitro and in vivo functional properties of native microglia In addition to their phenotypic and gene expression resemblance to nMG, murine iPS-MG also demonstrated the in vitro functional properties of nMG. Following stimulation with PMA, both cell types actively phagocytosed pHrodo E. coli BioParticles conjugates as evidenced by the acidification and resulting visualization of red fluorescent particles within circular intracellular structures (Fig. 6a) . The mean cell fluorescence intensities of nMG and iPS-MG after the addition of the pHrodo E. coli BioParticles were qualitatively similar, at 140,166.72 and 152,096.58 relative units respectively. Under baseline culture conditions, both nMG and iPS-MG generated ROS, as evidenced by the oxidation and resulting red fluorescence of the CellROX Deep Red reagent indicator dye within cells (Fig. 6b) . The mean cell fluorescence intensities after the addition of the CellROX reagent were 338,876.45 relative units for nMG and 235,213.10 relative units for iPS-MG. Control fibroblasts neither phagocytosed foreign particles nor produced ROS under the same conditions ( Fig. 6a,b) .
Migration to sites of CNS pathology such as brain tumors is an in vivo functional hallmark of microglia 24 . The ability of murine iPS-MG to migrate to and infiltrate experimental gliomas in mice was therefore assessed. One week following the intracranial implantation of syngeneic, luciferase-expressing malignant glioma cells, iPS-MG were injected into the cerebral hemisphere contralateral to the tumor site. Brains were immunohistochemically analyzed 1 week later, and luciferase-expressing tumor cells were found in areas of high nuclear density (Fig. 6c,g) . There was an expected abundance of infiltrating Iba1 + microglia in these areas (Fig. 6d,h) , and while many of them were GFPand represented native microglia ( Fig. 6e,i) , many were also Iba1 + GFP + and represented the iPS-MG cells previously injected into the contralateral hemisphere ( Fig. 6f,j) . These results demonstrate the ability of iPS-MG to engraft within an unconditioned brain and migrate from one hemisphere to the other in response to a tumor.
from Cx3cr1 Gfp/+ knock-in mice were used as a starting cell population. Expression of the fractalkine receptor CX3CR1 is a necessary, but not sufficient, criterion for defining murine microglia, and the microglia of Cx3cr1 Gfp/+ knock-in mice express GFP under control of the Cx3cr1 promoter 22 . GFP expression by iPS-MG was used to facilitate their in vitro and in vivo identification.
Cx3cr1 Gfp/+ iPSC express Oct4 but not CD34, CD11b or GFP ( Fig. 4b-d) . Following co-culture on OP9 murine stromal cell layers, cells were directed to an intermediate iPS-HPC (stage 1) state with loss of Oct4 expression and gain of CD34 expression ( Fig. 4e,f) . At stage 1, none of the co-cultured cells expressed either CD11b or GFP (Fig. 4g) . Subsequent culture of iPS-HPC on astrocyte monolayers supplemented with GM-CSF, M-CSF and IL-3 (stage 2) resulted in the appearance of GFP + cells in as early as 3 d (Fig. 4h-j) . These GFP + cells continued to increase in number over the following 7-14 d and required only biweekly media changes for maintenance. GFP + cells constituted ~4% of the mixed astrocyte-microglia cell culture (Supplementary Fig. 3) . Loss of CD34 expression and gain of CD11b expression occurred over this time period as well, consistent with the generation of murine disease-specific individuals and can also be expanded to large numbers in vitro. Additionally, a protocol using a myeloid rather than neuralcell intermediate state was purposely designed to be more consistent with the in vivo developmental lineage of microglia.
Our results above demonstrate the differentiation of both human and mouse iPSC into cells with not only the phenotype and consensus gene expression signature but also the in vitro and in vivo functional properties of primary brain-isolated microglia. In the correlation-based clustering analysis, the gene expression patterns of the murine iPS-MG most closely resembled those of neonatal microglia and next closely those of adult microglia. In contrast, in the human analysis, the human iPS-MG did not cluster as tightly with the commercially obtained human fetal microglia. Extraction of the individual gene expression data for the six consensus human microglia genes (P2RY12, GPR34, MERTK, C1QA, PROS1 and GAS6) from the microarray dataset did, however, demonstrate the high expression of all six genes in the iPS-MG but not in the iPSC, Mac, DC or commercially obtained human fetal microglia. While there are robust protocols for the isolation of murine microglia, similar protocols and source tissue for the isolation Murine iPS-MG increase the survival of intracranial malignant glioma-bearing mice The ability of native microglia to phagocytose tumor cell debris, load antigens onto major histocompatibility class II (MHC II) molecules and display costimulatory molecules such as B7-1 and B7-2 suggest their ability to present tumor antigens in vivo 25, 26 . Additionally, microglia are capable of directly killing tumor cells by producing nitric oxide, ROS and TNF-α (ref. 4) . As a potential clinical application of iPS-MG, we assessed the ability of intracranially injected nMG or iPS-MG, in combination with subcutaneously injected DC 27 , to prolong the survival of malignant glioma-bearing mice. C57BL/6 mice were intracranially implanted with syngeneic GL261 malignant glioma tumor cells expressing luciferase to facilitate the in vivo imaging of tumor size and growth. One week following implantation, animals were imaged to confirm tumor engraftment and randomized into five groups. Each control or treatment group was then injected intracranially (IC) and subcutaneously (SC) with different combinations of vehicle control (phosphate buffered saline; PBS) or cells (DC, nMG or iPS-MG) pulsed in vitro with tumor cell lysates, as shown in Supplementary Table 1 .
The median survival of the untreated control group (Group A: IC and SC injection of PBS) was 40 d, while that of the SC DC treated group (Group B) and IC nMG treated group (Group C) were 41 d (P = 0.859, log-rank test) and 46 d (P = 0.086, log-rank test), respectively. The combination IC nMG + SC DC treated group (Group D) had a median survival of 205.5 d (P = 0.008, log-rank test, degrees of freedom (df) = 1, χ 2 = 6.983) while the median survival of the IC iPS-MG + SC DC (Group E) group was undefined, as more than 50% of the animals were alive at the end of the 1-year observation period (P = 0.001, log-rank test, df = 1, χ 2 = 10.22). P-values were calculated in comparison to Group A ( Fig. 7 and Supplementary Table 1 ). Treatment of animals with cells pulsed in vitro with murine embryonic fibroblast lysates before injection did not prolong survival and demonstrated the antigen specificity of the antitumor treatments (data not shown).
DISCUSSION
Experimental mouse models of human diseases in which microglia have been genetically modified or ablated have been especially useful in demonstrating the beneficial and detrimental effects of microglia on the pathogenesis of a variety of brain and spinal cord disorders. A major obstacle to further laboratory study and clinical translation of these findings has been the lack of an abundant source of normal and disease-specific human microglia. One partial solution to overcoming this obstacle has been the differentiation of ES cells into microglia-like cells using a modified neuronal differentiation protocol. ES cells can be readily expanded to large numbers before differentiation, and mouse ES cell-derived microglia are capable of engrafting in the unconditioned CNS 23, [28] [29] [30] . While these protocols represent a significant advance in the study of microglia, they require several weeks to complete and do not mirror the normal microglial developmental process. In contrast to neurons and macroglia, microglia are of mesodermal rather than neuroectodermal origin and arise from embryonic yolk sac myeloid precursors that travel to the brain and spinal cord before differentiating into mature, functional cells within the CNS [31] [32] [33] . An analogous protocol for the differentiation of human ES cells has not been reported, and even if one were to be developed, the translation of ES cell-derived microglia to the clinical therapeutic setting would likely be constrained by the unavailability of patientspecific ES cells as a starting population, as well as histocompatibility issues and ethical concerns. To address these shortcomings, a protocol for the differentiation of human iPSC into microglia-like cells was developed. Human iPSC can be readily generated from normal and in amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder affecting adult motor neurons. Over 100 different SOD1 mutations have been identified, and the role of these mutations in human motor neuron and microglial function could be modeled using normal and diseasespecific iPS-MG 36 . iPS-MG could also be used in high-throughput screens of SOD1-active drugs and microglia-specific toxicity assays. Another potential application of human iPS-MG is their use in personalized medicine applications. The murine iPS-MG generated here were able to engraft within an unconditioned brain and migrate to an area of pathology. Furthermore, the murine iPS-MG, in combination with DC, were an effective cell therapy for intracranial malignant glioma tumors. iPS-MG could also potentially be used for the treatment of diseases such as ALS or as a delivery vector for gene-based therapies of diseases such as multiple sclerosis or Parkinson's disease 16, 17, 28, 36 .
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. of authentic human microglia are currently lacking. This underscores the need for protocols such as ours. Very recently, another protocol for the differentiation of human iPSC and ES cells into microglia-like cells was reported 34 . Similarly to ours, in the protocol developed by Muffat et al., cells are differentiated through a myeloid rather than neural intermediate, and the final yields of microglia-like cells from a given number of starting iPSC are also similar. The major advantage of the other method appears to be the use of defined factors rather than co-culture with astrocytes to induce final differentiation. The use of astrocytes derived from the same starting iPSC as that used to make the microglia-like cells would, however, avoid the introduction of any allogeneic cells into the differentiation process, an important consideration for potential clinical uses. An apparent advantage of our astrocyte co-culture protocol compared to the defined-factor protocol is the use of starting iPSC propagated under serum-and feederfree conditions rather than grown on a feeder layer of murine embryonic fibroblasts. The avoidance of any xenogeneic cells in the differentiation process may facilitate the future clinical use of human microglia-like cells. An additional difference in the two protocols is the time required for the differentiation of the iPSC into microglia-like cells. Whereas our mouse and human protocols require 2 and 4 weeks, respectively, the defined-factor protocol requires 8 weeks for both species. Finally, the microglia-like behavior of the cells generated using the defined-factor protocol was demonstrated using an elegant in vitro 3D organotypic neuroglial environment. In contrast, we demonstrated the engraftment, migration and potential clinical use of our microglia-like cells in an in vivo model that did not require myeloablative conditioning of the host animal with lethal irradiation.
The potential applications of normal and disease-specific human iPS-MG include their use in disease modeling, drug discovery studies and toxicity screening assays 35 . Genetic mutations of microglia-expressed genes have been associated with the pathogenesis and prognosis of a variety of human diseases. Microglia derived from the iPSC of patients with such diseases may allow direct study of the roles of those gene products in disease development and progression. One such example is superoxide dismutase-1 (SOD1), a mutation of which is implicated Supplementary Table 1 . Statistical analysis for the survival curves was carried out using the logrank test. P < 0.05, calculated in comparison to Group A, was considered statistically significant. For Group D (IC nMG + SC DC): P = 0.008, log-rank test, df = 1, χ 2 = 6.983; for Group E (IC iPS-MG + SC DC): P = 0.001, logrank test, df = 1, χ 2 = 10.22 (n = 10 animals for each group). macrophages were isolated following culture of whole bone marrow with recombinant murine IL-4 (RND Systems)-and GM-CSF (Peprotech)-containing media or M-CSF (Peprotech)-containing media, respectively. Peritoneal macrophages were harvested by saline lavage. Neural stem cells were purchased from Millipore. Firefly luciferase-expressing GL261 cells (National Cancer Institute) were cultured in Neurobasal media (Gibco), supplemented with N2 and B27 additives (Gibco), Glutamax and penicillin/streptomycin. NCRM-5 and iNC-01 human iPSCs were maintained as feeder-free on matrigel (BD)-coated six-well plates and split every 3 d. The cells were split 1:6 or 1:12 using EDTA (0.5 mM in Ca 2+ -and Mg 2+ -free PBS with 1.8 mg/mL NaCl). Essential 8 (Invitrogen) medium was used for growth and maintenance of NCRM-5 human iPSC and were maintained in a humidified 37 °C incubator with 5% CO 2 and 21% O 2 (ref. 39). mTESR (StemCell Technologies) media was used for iNC-01 cells. The cell lines were regularly tested for mycoplasma contamination using MycoAlert Mycoplasma Detection Kit (Lonza).
Microglial differentiation
Human iPSC myeloid differentiation on OP9 feeder layers. NCRM-5 human iPSCs were harvested from a well of a six-well plate using EDTA according to Chen et al. 39 and resuspended in OP9 differentiation medium (ODM-MEMα with 20% FBS and 100 µM MTG). All steps were cultured in a humidified 37 °C incubator with 5% CO 2 and 21% O 2 . On day 0, iPSC aggregates were added to a confluent OP9 (ATCC) plate. On day 1, medium was removed, and 20 mL of fresh ODM was added to the plate. On days 4 and 6, half of the medium was replaced with fresh medium. On day 9, cells were harvested using 5 mL of collagenase solution (1 mg/mL) by incubating it for 30 min at 37 °C (Life Technologies). Next, collagenase was aspirated, and 5 mL of trypsin/EDTA solution (0.05%/0.5 mM) was added and incubated for 15 min at 37 °C. Cell suspension was collected, and MACS sort of CD34 + /CD43 + cells was carried out according to Miltenyi manufacturer's directions. Subsequently, the pellet from the previous step was resuspended using myeloid progenitor expansion medium (ODM with 200 ng/mL GM-CSF (Berlex)) at a concentration of ~5.0 × 10 4 cells/mL. pHEMA-coated T75 flasks were washed with 20 mL PBS and 10-20 mL of CD34 + cell suspension was added and incubated for 2 d. On day 11, expanded CD34 + cells were centrifuged and resuspended in astrocyte differentiation medium (ADM-IMDM with 10% FBS, 20 ng/mL GM-CSF, 20 ng/ mL M-CSF (Peprotech) and 20 ng/mL IL3 (Peprotech)). Expanded CD34 + cells were plated onto confluent 10-cm plates of human astrocytes at a density of 1-2 × 10 5 cells/10 mL/plate. On day 15, 10 mL of ADM was added. On days 18-25, media was aspirated and plates were harvested using 5 mL of trypsin/EDTA and incubated for 5-10 min. Subsequently, cell suspensions harvested from the plates were washed and MACS-sorted for CD11b + cells according to the manufacturer's directions. The CD11b + cells were collected and resuspended using ADM; they were used for further characterization, expansion or in experiments as required.
Feeder-free differentiation of human iPSC-microglia on astrocytes. iNC-01 human iPSC were cultured feeder-free in mTESR1 media (Stemcell Technologies). Human iPSCs were passaged when 70% confluent, using PBS/EDTA/NaCl to loosen colonies from the plate, and replated onto a matrigel-coated plate at ratios of 1 Fig. 4a-e ). Karyotype analysis revealed the cells to be 40,XY ( Supplementary  Fig. 4f ). All animal usage was approved by the NINDS/NIDCD Animal Care and Use Committee. Human iPSC NCRM-5 was established from human cord bloodderived CD34 + cells using episomal plasmids (Lonza contract) made available to NIH Center for Regenerative Medicine and currently available through RUCDR Infinite Biologics. The iNC-01 cell line was obtained from Dr. H.L. Malech's laboratory of Host Defenses and Research Technologies Branch, NIAID, NIH. The iNC-01 cells were reprogrammed from human peripheral blood hematopoietic stem/progenitor cells (CD34 + ) cells that had been mobilized into the donor's peripheral blood by G-CSF treatment. The reprogramming method involved transduction with integrating STEMCCA-loxP lentivirus expressing human Oct4Klf4/Sox2/c-myc from a single transcript, followed by Cre-mediated excision of the vector 37 . Authentication and characterization of the cell line as iPSC arising from the healthy donor included 38 TRA-1-60 and alkaline phosphatase staining for pluripotency markers, three-germ layer characterization by teratoma formation in immunodeficient NSG mice followed by H&E staining and histology characterization, three-germ layer characterization by embryoid body differentiation and immunofluorescence microscopy after staining for smooth muscle actin (mesoderm), α-fetoprotein (endoderm) and class III b-tubulin (ectoderm). Additional characterization included DNA fingerprinting to confirm that the origin of the cells matched the donor blood sample by DNA microsatellite analysis at seven loci in comparison with PBMCs derived from that patient using the AmpFLSTR COfiler kit (Applied Biosystems) and genome-wide DNA methylation analysis at > 485,000 CpG methylation sites in comparison with embryonic stem cells, other iPSC lines and primary hematopoietic cells using Infinium HumanMethylation450 BeadChip (Illumina). The iNC-01 iPSC line was further characterized molecularly for additional pluripotency markers by global proteome analysis using electrospray ionization mass spectrometry (ESI-MS) and MALDI-TOF/TOF mass spectrometry in comparison with embryonic stem cells, other iPSC lines and somatic cells 38 and by expression analysis of 754 microRNAs using the TaqMan Human MicroRNA Array A+B v3.0.
Cell culture. Cx3cr1 Gfp/+ iPSC were maintained on a mitotically inactivated C57BL/6-background MEF feeder layer (Globalstem) using Knockout DMEM with 10% ES-qualified FBS, nonessential amino acids, sodium pyruvate, 2-mercaptoethanol, penicillin/streptomycin (all from Gibco) and leukemia inhibitory factor (LIF; Millipore). iPSCs were passaged onto fresh MEF layers every 3 d. Primary mouse astrocytes were isolated from postnatal day 5 C57BL/6 mice using an Astrocyte Isolation Starter Kit (Miltenyi) as per the manufacturer's instructions and maintained in animal astrocyte media (Lonza), supplemented with astrocyte growth supplement (Lonza), FBS and penicillin/streptomycin as per the manufacturer's instructions. Media was changed every other day and astrocytes were passaged at a 1:5 ratio upon reaching confluency. OP9 stromal cells (CRL-2749, ATCC) were maintained in α-MEM media (Gibco) supplemented with 20% FBS and penicillin/streptomycin on 0.1% gelatin-coated tissue culture treated dishes (Sigma). Media was changed twice weekly, and OP9 cells were passaged upon reaching confluency. Normal nMG were isolated from postnatal day 2 brains using the Neural Tissue Dissociation Kit and CD11b MicroBeads (Miltenyi) according to manufacturer's directions and cultured in DMEM (Life Technologies) with 10% FBS, Glutamax, nonessential amino acids, sodium pyruvate, 2-mercaptoethanol (Gibco) and sodium bicarbonate (Sigma). Microglia were plated on six-well temperature-responsive tissue culture plates (Upcell) at 2 × 10 6 cells per well in 2 mL of media. Adult murine microglia were purified from mixed glial cultures. Dendritic cells and bone marrow-derived
